CytomX Research Program Target definition

CytomX Research Program Target means the Target selected by CytomX (other than an ImmunoGen Excluded Target) for inclusion in the Research Program in accordance with Section 2.1 hereof. A Target ceases to be a CytomX Research Program Target once (a) it has become the subject of a Development and Commercialization License in accordance with Section 3.2.2 hereof or (b) it has been dropped from the Research Program in accordance with Section 2.1.3 hereof.
Sample 1Sample 2Sample 3

Examples of CytomX Research Program Target in a sentence

  • If CytomX does not provide ImmunoGen with an Option Exercise Notice with respect to its Research Program Target during the Term and prior to the CytomX Option Exercise Cut-Off Date, then the applicable Target shall no longer be considered a CytomX Research Program Target.

  • Notwithstanding the foregoing, the CytomX Option Exercise Cut-Off Date with respect to the CytomX Research Program Target shall be the [***] day after the Replacement Target Cut-Off Date if CytomX has not notified ImmunoGen on or prior to the Replacement Target Cut-Off Date of its intention to replace such CytomX Research Program Target with a Replacement Target in accordance with Sections 2.1.2 and 2.1.3 hereof.

  • Each Work Plan shall be approved by the JRC within [***] days of the Effective Date for the initial CytomX Research Program Target and the first initial ImmunoGen Research Program Target listed on Exhibit A hereof or as determined by the JRC with respect to the second initial ImmunoGen Research Program Target.

  • The Non- Executive Directors shall also be entitled to profit related commission in addition to the sitting fees.

  • Each Work Plan shall be approved by the JRC within thirty (30) days of the Effective Date for the initial CytomX Research Program Target and the first initial ImmunoGen Research Program Target listed on Exhibit A hereof or as determined by the JRC with respect to the second initial ImmunoGen Research Program Target.

  • Notwithstanding the foregoing, the CytomX Option Exercise Cut-Off Date with respect to the CytomX Research Program Target shall be the sixtieth (60th) day after the Replacement Target Cut-Off Date if CytomX has not notified ImmunoGen on or prior to the Replacement Target Cut-Off Date of its intention to replace such CytomX Research Program Target with a Replacement Target in accordance with Sections 2.1.2 and 2.1.3 hereof.

  • EXHIBIT A CytomX Research Program Target ** [***] UniProtKB/Swiss Prot [***] UniProtKB/Swiss Prot [***] for purposes of this Agreement only to the extent that the Agreement Probody incorporated into the CytomX Agreement PDC [***] ImmunoGen Research Program Targets [***] UniProtKB/Swiss Prot [***] UniProtKB/Swiss Prot [***] ***Certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission.

  • EXHIBIT A CytomX Research Program Target [***]UniProtKB/Swiss Prot [***]UniProtKB/Swiss Prot [***] PDC [***] ImmunoGen Research Program Targets [***]UniProtKB/Swiss Prot [***]UniProtKB/Swiss Prot [***] ***Certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission.

  • During the Research Term, ImmunoGen will not, and will cause its Affiliates not to, research, develop, or commercialize any ADC Targeted to the CytomX Research Program Target and will not, and will cause its Affiliates not to, license ImmunoGen Technology to any Third Party to research, develop or commercialize any product comprising an ADC Targeted to the CytomX Research Program Target.

Related to CytomX Research Program Target

  • Research Program Term has the meaning set forth in Section 2.2.

  • Research Program has the meaning set forth in Section 2.1.

  • Collaboration Target means the Initial Collaboration Targets set forth on Exhibit F and any Additional Target or Substitute Target that is selected in accordance with Section 3.3 of this Agreement.

  • Collaboration Compound means any of the following: (a) FG-4592, (b) any HIF Compound (other than FG-4592) that is added to this Agreement pursuant to Section 3.6, and (c) any salts, esters, complexes, chelates, crystalline and amorphous morphic forms, pegylated forms, enantiomers (excluding regioisomers), prodrugs, solvates, metabolites and catabolites of any of the foregoing ((a) or (b)).

  • Research Plan shall have the meaning set forth in Section 2.1.

  • Development Candidate means a Compound that meets the Development Candidate Criteria for the initiation of a Development Program for the treatment of CF, and which is the subject of a notice from Vertex to CFFT that Vertex intends to commence formal pre-clinical development of the Compound in the Field pursuant to the provisions of Section 3.1 hereof.

  • Research Project means a discrete scientific endeavor to answer a research question or a set of research questions related to medical marijuana and is required for a medical marijuana research license.

  • Collaboration Know-How means all Know-How conceived, discovered, developed or otherwise made by or on behalf of a particular Party or any of its Affiliates or permitted subcontractors of any of the foregoing (solely or jointly by or on behalf of a particular Party or any of its Affiliates or permitted subcontractors of any of the foregoing) in the course of [***].

  • Research Term has the meaning set forth in Section 3.2.

  • Development Program means the implementation of the development plan.

  • Collaboration has the meaning set forth in Section 2.1.

  • Collaboration Product means a pharmaceutical product containing or comprising Compound in any dosage form alone, or in combination with, one or more other pharmaceutically active ingredients, and any and all Improvements thereto.

  • Lead Compound means any compound of lead other than galena which, when treated in the manner described below, yields to an aqueous solution of hydrochloric acid a quantity soluble lead compound exceeding, when calculated as lead monoxide, five percent of the dry weight of the portion taken analysis.

  • Product Candidate means each of MYO-101, MYO-102, MYO-103, MYO-201 and MYO-301, as defined on Exhibit B, in each case in any form or formulation.

  • GSK will have the meaning set forth in the Preamble.

  • Licensed Compounds means any EZH2 Compound(s) that is:

  • ISIS means the department’s individualized services information system.

  • Research Period means the research period as described in the Commissioned Research Plan. In accordance with the provisions of this Agreement, in the event that the Agreement ended prior to the completion date of the research originally set, the date the Agreement ends shall be read as the research period.

  • Licensed Compound means (a) 3,4-Diaminopyridine, the chemical structure of which is set forth on Exhibit B-2; and (b) any derivatives, isomers, metabolites, prodrugs, acid forms, base forms, salt forms, or modified versions of such compound in (a).

  • Licensed Program means the executable processing programs of licensed information, which is composed of various modules in the Licensed Software package provided by the Licensor.

  • Collaboration IP means Collaboration Know-How and Collaboration Patents.

  • Collaboration Patent Rights means Patent Rights claiming Collaboration Know-How.

  • Collaboration Term has the meaning set forth in Section 2.2.

  • Program Technology means Program Know-How and Program Patents.

  • BMS means the Company, all related companies, affiliates, subsidiaries, parents, successors, assigns and all organizations acquired by the foregoing.

  • Collaboration Patents means any and all Patents that claim or cover any of the Collaboration Know-How.